Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2018-04-25
|
AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) |
spinal muscular atrophy (SMA) Type 1, 2, 3 |
3 |
Avexis (USA - IL) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-04-24
|
AVXS-101 |
spinal muscular atrophy (SMA) Type 1 |
1 |
Avexis (USA - TX) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-04-24
|
AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) |
spinal muscular atrophy (SMA) Type 1 |
3 |
Avexis (USA - IL) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-04-23
|
Vabomere™ (formerly known as Carbavance) meropenem-vaborbactam |
complicated urinary tract infections (cUTI) |
3 |
Melinta Therapeutics (USA - CT) |
Infectious diseases |
2018-04-23
|
RX-P2382 |
|
preclinical |
Melinta Therapeutics (USA - CT) |
Infectious diseases |
2018-04-23
|
omadacycline |
community-acquired bacterial pneumonia (CABP) |
3 |
Paratek Pharmaceuticals (USA - MA) |
Infectious diseases |
2018-04-17
|
ATOR-1015 |
|
preclinical |
Alligator Bioscience (Sweden) |
Cancer - Oncology |
2018-04-17
|
Aimovig™ - AMG 334 (erenumab) |
migraine |
3b |
Amgen (USA - CA) Novartis (Switzerland) |
CNS diseases |
2018-04-17
|
monalizumab (IPH2201) and cetuximab |
squamous cell carcinoma of the head and neck |
preclinical |
Innate Pharma (France) |
Cancer - Oncology |
2018-04-17
|
monalizumab and durvalumab |
solid tumors |
preclinical |
Innate Pharma (France) |
Cancer - Oncology |
2018-04-17
|
antibody against Siglec-9 |
|
preclinical |
Innate Pharma (France) |
Cancer - Oncology |
2018-04-17
|
IPH52 and IPH53 |
|
preclinical |
Innate Pharma (France) |
Cancer - Oncology |
2018-04-17
|
monalizumab (IPH2201) and cetuximab |
relapsed or metastatic squamous cell cancer of the head and neck (SCCHN) |
1b-2 |
AstraZeneca (UK) Innate Pharma (France) |
Cancer - Oncology |
2018-04-16
|
tislelizumab (BGB-A317) |
relapsed or refractory mature T- and natural killer (NK)-cell lymphomas |
2 |
BeiGene (China) |
Cancer - Oncology |
2018-04-16
|
pamiparib (BGB-290) |
locally advanced or metastatic high-grade non-mucinous ovarian cancer (HGOC), including fallopian cancer, or triple-negative breast cancer (TNBC), who had disease progression following at least one line of chemotherapy |
1 |
BeiGene (China) |
Cancer - Oncology |
2018-04-13
|
MIV-818 |
hepatocellular carcinoma and other liver cancers |
preclinical |
Medivir (Sweden) |
Cancer - Oncology |
2018-04-12
|
PF-06939926 (mini-dystrophin) Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene |
Duchenne muscular dystrophy (DMD) |
1b |
Pfizer (USA - NY) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-04-12
|
AB-506, AB-452 in combination with ARB-1467 and approved HBV therapies |
hepatitis B |
preclinical |
Arbutus Biopharma (Canada) |
Infectious diseases |
2018-04-10
|
tislelizumab (BGB-A317) |
previously treated advanced hepatocellular carcinoma |
2 |
BeiGene (China) |
Cancer - Oncology |
2018-04-09
|
tazemetostat - EPZ-6438 (E7438) |
advanced solid tumors and B-cell non-Hodgkin lymphoma (NHL) |
1 |
Epizyme (USA - MA) |
Cancer - Oncology |